Article

Chronic Low Back Pain Drug Is Abuse-Resistant

Author(s):

Purdue Pharma L.P. has developed an abuse-resistant drug to treat chronic low back pain.

An abuse-resistant opioid analgesic, hydrocodone bitartrate, has been successfully developed to combat chronic low back pain, according to a statement from Purdue Pharma L.P.

In a phase 3 study, scientists evaluated 588 opioid-naïve and opioid-experienced patients with moderate to severe chronic low back pain for 12 weeks. The weekly average score for pain was 7.4 on a scale of 0-10 (10 being maximum pain). The drug dosage was increased once every 3-5 days if necessary until a stabilized once-daily dose was identified (20-120 mg).

A majority of the study’s participants demonstrated at least a 30% improvement of pain intensity and almost half of patients reached 50% improvement. Common side effects after taking the drug were common opioid analgesic side effects including constipation, nausea, vomiting, dizziness, and headache.

Hydrocodone bitartrate contains properties intended to make the tablets harder to manipulate for snorting and intravenous injection purposes.

Purdue Pharma intends to file a New Drug Application with the US Food and Drug Administration later in 2014 requesting approval to market the drug.

Related Videos
Uncovering the Role of COVID-19 in Rheumatic Disease, with Leonard Calabrese, DO
Comparing Treatment Options for Psoriatic Arthritis with Philip Mease, MD
Considering Viral Infections in Patients With Rheumatic Disease With Leonard Calabrese, DO
Leonard H. Calabrese, DO, Professor of Medicine and Vice Chair, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University
Developing Risk Assessment Tools for Viruses in School
Alvin Wells, MD, PhD: Making Informed Treatment Decisions With New Testing Strategies
Alvin Wells, MD, PhD
Upcoming Research in PsA, AxSpa, with Philip Mease, MD
© 2024 MJH Life Sciences

All rights reserved.